ART-LP04-02 ยท ART-LP04
Understand how donor and surrogate screening domains differ, why eligibility rules vary, and why screening reduces but never eliminates risk. Clear decisions begin by separating what is observed, why it matters, how the process works and which uncertainty remains.
Visual lesson summary
Review the lesson as a carousel.
Swipe or scroll through the key ideas, then continue with the detailed guidance below.
01 / 07Screening Eligibility and Residual Risk 
02 / 07Why it matters 
03 / 07How the method works 
04 / 07How to read the evidence 
05 / 07What this cannot decide 
06 / 07Use a decision record 
07 / 07Keep the evidence visible
Define the exact question
Compare medical, reproductive, genetic, infectious, psychological, social and records review for gamete donors and gestational carriers, including program and regulatory criteria.
Precision starts by defining the object, method and decision separately. For screening eligibility and residual risk, useful records include Address sensitivity, prevalence, predictive value, genetic residual risk. Each item should state who produced it, when it was produced, what population or specimen it represents, and which conclusion it can support. A familiar label may hide different assays, laboratory policies, legal meanings or endpoints, so the reader should ask for the operational definition rather than infer one from the name.
Why the distinction changes decisions
Eligibility blends safety evidence, professional judgment, law, program policy and fairness; passing a screen is not a guarantee of health, pregnancy or future behavior.
The practical consequence is specific: misunderstanding screening eligibility and residual risk can change which question is asked, which comparison appears favourable, or who seems to own the decision. Separate observed facts from interpretation and interpretation from choice. Record what remains unknown, what would change the conclusion and which excluded question belongs elsewhere: Assessing a particular donor or surrogate; Detailed matching preferences; Treatment-cycle medical protocols. This keeps uncertainty visible without turning it into either alarm or reassurance.
How the process should work
Map each screen to the person protected, hazard addressed, evidence source, result pathway, expiry or update rule, and residual risk after acceptance.
Then test the method against one routine case and one discordant or incomplete case. Record where Address sensitivity, prevalence, predictive value enter the sequence, who interprets them, what can delay the next step and which result would require the question to be reframed rather than forced into a yes-or-no answer.
Read measures without overreaching
Advanced interpretation should address Address sensitivity, prevalence and predictive value; genetic residual risk; infectious windows; obstetric-history prediction; psychological assessment validity; threshold drift and equity impacts.. The purpose is to show how the method works, where variation enters, which comparisons are defensible and what the evidence cannot establish. Keep Address sensitivity, prevalence, predictive value, genetic residual risk, infectious windows tied to their source, population and decision context; avoid universal thresholds, retrospective certainty and individual predictions from population averages.
Match evidence to the claim
Evidence must fit the exact claim in screening eligibility and residual risk. Guidance can describe consensus or recommended process; a registry can describe observed outcomes; a systematic review can synthesize eligible studies; and a primary study can test a narrower question. Check version, population, endpoint, denominator, missing data, uncertainty and transferability before treating a source as decisive.
Trace each public statement to a stable claim ID and the source records that support it. Compare Address sensitivity, prevalence, predictive value, genetic residual risk only when methods and populations are sufficiently alike. If a source addresses process but not effectiveness, safety but not legal effect, or a group average but not individual prediction, state that boundary directly.
Keep professional roles visible
For screening eligibility and residual risk, professional roles are limited and complementary. An editorial reviewer checks scope discipline, plain-language accuracy, accessibility and whether wording overstates the evidence. A qualified clinician checks clinical terminology, interpretation limits, safety boundaries and escalation language. A genetics professional checks test purpose, result categories, inheritance language, counselling boundaries and residual risk. A psychological reviewer checks voluntariness, relationship effects, support needs and non-coercive language. A qualified local reviewer checks the named location, current rule, applicability and review date. None of these roles replaces the informed choice of the person whose body, gametes, embryos, records, legal position or family life is affected. Record disagreements and conflicts of interest instead of hiding them behind a collective recommendation.
Build a decision record
Ask which criterion is mandatory or discretionary, who reviews exceptions, what new information triggers reassessment, and how declined applicants are informed.
A usable decision record for screening eligibility and residual risk names the exact question, the affected person, the available options, the evidence and its limits, the professional responsible for interpretation, and the condition that would reopen the choice. It also records what is not yet known and whether the next step is reversible. The record should never convert a population estimate into a personal forecast, a laboratory category into a guarantee, a program policy into consent, or one jurisdiction's rule into universal law.
- Ask which criterion is mandatory or discretionary, who reviews exceptions, what new information triggers reassessment, and how declined applicants are informed.
- Confirm the source and update date for screening, eligibility, residual.
- Record what compare, medical, reproductive can and cannot decide.
- Route unresolved questions to editorial, medical, genetic, psychological, jurisdictional.
For Nerds: Technical Deep Dive
Address sensitivity, prevalence and predictive value; genetic residual risk; infectious windows; obstetric-history prediction; psychological assessment validity; threshold drift and equity impacts.
Mechanism, measurement and endpoint
Address sensitivity, prevalence and predictive value; genetic residual risk; infectious windows; obstetric-history prediction; psychological assessment validity; threshold drift and equity impacts. Advanced interpretation starts by defining construct, measurement and endpoint. The relevant technical vocabulary includes screening, eligibility, residual, compare, medical, reproductive, genetic, infectious, psychological, social, records, review. These terms describe different layers: biological mechanism, observable signal, operational category, decision threshold and patient-relevant outcome. A strong analysis does not move between those layers without evidence. It records specimen or document provenance, analytical method, timing, comparison population, missingness, uncertainty and the professional who owns interpretation. It also asks whether the source is guidance, regulation, registry data, systematic review or primary research, because each supports different inferences. For genetic, preserve the numerator, denominator, reference frame and failure modes. Test sensitivity, specificity, calibration, interobserver variation, selection bias, confounding and jurisdictional drift can each make a technically correct statement misleading in another context. A reviewer should verify current terminology and identify the evidence that would change the decision rather than adding unsupported precision.
- Compare medical, reproductive, genetic, infectious, psychological, social and records review for gamete donors and gestational carriers, including program and regulatory criteria.
- Map each screen to the person protected, hazard addressed, evidence source, result pathway, expiry or update rule, and residual risk after acceptance.
- Ask which criterion is mandatory or discretionary, who reviews exceptions, what new information triggers reassessment, and how declined applicants are informed.
Expected ranges / examples
- Topic-specific interpretation sequence: screening -> eligibility -> residual -> compare -> medical. A non-numeric process example showing why adjacent observations and decisions must not be treated as equivalent. Source: ASRM gamete and embryo donation.
Methods, categories and uncertainty
Map each screen to the person protected, hazard addressed, evidence source, result pathway, expiry or update rule, and residual risk after acceptance. Advanced interpretation starts by defining construct, measurement and endpoint. The relevant technical vocabulary includes screening, eligibility, residual, compare, medical, reproductive, genetic, infectious, psychological, social, records, review. These terms describe different layers: biological mechanism, observable signal, operational category, decision threshold and patient-relevant outcome. A strong analysis does not move between those layers without evidence. It records specimen or document provenance, analytical method, timing, comparison population, missingness, uncertainty and the professional who owns interpretation. It also asks whether the source is guidance, regulation, registry data, systematic review or primary research, because each supports different inferences. For psychological, preserve the numerator, denominator, reference frame and failure modes. Test sensitivity, specificity, calibration, interobserver variation, selection bias, confounding and jurisdictional drift can each make a technically correct statement misleading in another context. A reviewer should verify current terminology and identify the evidence that would change the decision rather than adding unsupported precision.
- Compare medical, reproductive, genetic, infectious, psychological, social and records review for gamete donors and gestational carriers, including program and regulatory criteria.
- Map each screen to the person protected, hazard addressed, evidence source, result pathway, expiry or update rule, and residual risk after acceptance.
- Ask which criterion is mandatory or discretionary, who reviews exceptions, what new information triggers reassessment, and how declined applicants are informed.
Expected ranges / examples
- Topic-specific interpretation sequence: eligibility -> residual -> compare -> medical -> reproductive. A non-numeric process example showing why adjacent observations and decisions must not be treated as equivalent. Source: ASRM gamete and embryo donation.
Limits, review and decision ownership
Ask which criterion is mandatory or discretionary, who reviews exceptions, what new information triggers reassessment, and how declined applicants are informed. Advanced interpretation starts by defining construct, measurement and endpoint. The relevant technical vocabulary includes screening, eligibility, residual, compare, medical, reproductive, genetic, infectious, psychological, social, records, review. These terms describe different layers: biological mechanism, observable signal, operational category, decision threshold and patient-relevant outcome. A strong analysis does not move between those layers without evidence. It records specimen or document provenance, analytical method, timing, comparison population, missingness, uncertainty and the professional who owns interpretation. It also asks whether the source is guidance, regulation, registry data, systematic review or primary research, because each supports different inferences. For infectious, preserve the numerator, denominator, reference frame and failure modes. Test sensitivity, specificity, calibration, interobserver variation, selection bias, confounding and jurisdictional drift can each make a technically correct statement misleading in another context. A reviewer should verify current terminology and identify the evidence that would change the decision rather than adding unsupported precision.
- Compare medical, reproductive, genetic, infectious, psychological, social and records review for gamete donors and gestational carriers, including program and regulatory criteria.
- Map each screen to the person protected, hazard addressed, evidence source, result pathway, expiry or update rule, and residual risk after acceptance.
- Ask which criterion is mandatory or discretionary, who reviews exceptions, what new information triggers reassessment, and how declined applicants are informed.
Key takeaways
- Compare medical, reproductive, genetic, infectious, psychological, social and records review for gamete donors and gestational carriers, including program and regulatory criteria.
- Eligibility blends safety evidence, professional judgment, law, program policy and fairness; passing a screen is not a guarantee of health, pregnancy or future behavior.
- Map each screen to the person protected, hazard addressed, evidence source, result pathway, expiry or update rule, and residual risk after acceptance.
- Ask which criterion is mandatory or discretionary, who reviews exceptions, what new information triggers reassessment, and how declined applicants are informed.
FAQ
What exactly is Screening Eligibility and Residual Risk?
Compare medical, reproductive, genetic, infectious, psychological, social and records review for gamete donors and gestational carriers, including program and regulatory criteria.
Why does the distinction matter?
Eligibility blends safety evidence, professional judgment, law, program policy and fairness; passing a screen is not a guarantee of health, pregnancy or future behavior.
How should the review work?
Map each screen to the person protected, hazard addressed, evidence source, result pathway, expiry or update rule, and residual risk after acceptance.
What belongs in the advanced evidence review?
Address sensitivity, prevalence and predictive value; genetic residual risk; infectious windows; obstetric-history prediction; psychological assessment validity; threshold drift and equity impacts.
What is outside this scope?
This package does not decide Assessing a particular donor or surrogate; Detailed matching preferences; Treatment-cycle medical protocols. Those questions require their own evidence, scope and responsible professional.
What should be recorded before a decision?
Ask which criterion is mandatory or discretionary, who reviews exceptions, what new information triggers reassessment, and how declined applicants are informed.